Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gleave

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinonesD M Gleave, S J Brickner, P R Manninen, et al.
Oncogene|January 27, 2010
Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Oncogene|August 7, 2025
Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Oncogene|April 10, 2025
Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Oncogene|April 23, 2013
The role of DAB2IP in androgen receptor activation during prostate cancer progressionK Wu, J Liu, S-F Tseng, et al.
Scientific Reports|August 5, 2018
A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4BD Bosc, L Vezenkov, S Bortnik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinonesD M Gleave, S J Brickner, P R Manninen, et al.
Oncogene|January 27, 2010
Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Oncogene|August 7, 2025
Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Oncogene|April 10, 2025
Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4EC Andrieu, D Taieb, V Baylot, et al.
Cell Death & Disease|October 30, 2015
DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosisJ Zhou, Z Ning, B Wang, et al.
Oncogene|April 23, 2013
The role of DAB2IP in androgen receptor activation during prostate cancer progressionK Wu, J Liu, S-F Tseng, et al.
Scientific Reports|August 5, 2018
A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4BD Bosc, L Vezenkov, S Bortnik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 4